Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics

Transfusion

Volumn 51, Issue 10, 2011, Pages 2175-2182

  Li, Jie ^a   Hamilton, Ellie ^a   Vaughn, Louette ^a   Graiser, Michael ^a   Renfroe, Heather ^a   Lechowicz, Mary Jo ^a   Langston, Amelia ^a   Prichard, Jefferson Mark ^a   Anderson, Darlene ^a   Gleason, Charise ^a   Lonial, Sagar ^a   Flowers, Christopher R ^a   Kaufman, Jonathan L ^a   Waller, Edmund K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BLOOD CELL COUNT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; ENGRAFTMENT; FEMALE; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MYELOMA; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 80051977567     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03136.x     Document Type: Article

References (21)

1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V,; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-71. (Pubitemid 34680969)
2. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet JP, Gisselbrecht C,. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999; 17: 222-9. (Pubitemid 29022397)
3. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P,; Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-33.
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R,. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-7. (Pubitemid 26240110)
5. Moog R,. Mobilization and harvesting of peripheral blood stem cells. Curr Stem Cell Res Ther 2006; 1: 189-201.
6. Pusic I, DiPersio JF,. The use of growth factors in hematopoietic stem cell transplantation. Curr Pharm Des 2008; 14: 1950-61.
7. Perea G, Sureda A, Martino R, Altés A, Martínez C, Cabezudo E, Amill B, Martín-Henao GA, González Y, Muñoz L, Peyret M, Brunet S, Sierra J,. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001; 80: 592-7. (Pubitemid 33061999)
8. Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E,. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907-12. (Pubitemid 38660123)
9. Akhtar S, Weshi AE, Rahal M, Khafaga Y, Tbakhi A, Humaidan H, Maghfoor I,. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008; 49: 769-78. (Pubitemid 351517224)
10. Traynor K,. Plerixafor approved for autologous hematopoietic stem-cell transplantation. Am J Health Syst Pharm 2009; 66: 112.
11. Flomenberg N, DiPersio J, Calandra G,. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 2005; 114: 198-205. (Pubitemid 41567002)
12. Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J,. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1253-61.
13. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G,; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-73.
14. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G,; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-6.
15. Duarte RF, Shaw BE, Marin P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazõn JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH,. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52-8.
16. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K, Nelson V, Kovacsovics T, Leis J, Calandra G, Maziarz RT,. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009; 43: 909-17.
17. Hicks ML, Lonial S, Langston A, Flowers C, Roback JD, Smith KJ, Mossavi Sai S, Teagarden D, Hamilton ES, Waller EK, Kaufman J,. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion 2007; 47: 629-35. (Pubitemid 46449623)
18. Urosevic I, Balint B, Popovic S,. [Peripiheral blood hematopoietic stem cells-biology, apheresis collection and cryopreservation]. Med Pregl 2007; 60: 42-7.
19. National Marrow Donor Program and The Medical College of Wiscosin. CIBMTR Forms Manual: Post-TED Form 2450. [cited 2010 Mar 29]. Available from: URL
20. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, Dan E, Taioli S, Giudice V, Agis H, Kopetzky G, Soutar R, Casadei B, Baccarani M, Lemoli RM,. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-63.
21. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK,. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-9.